How to Use ALP in Diagnosing or Ruling Out Paget's Disease
Serum alkaline phosphatase (ALP) should be measured after radiological confirmation of Paget's disease, not as a primary diagnostic tool—plain radiographs of suspicious skeletal regions are required first to establish the diagnosis. 1
Diagnostic Algorithm
Step 1: Initial Diagnosis Requires Imaging First
- Plain radiographs are mandatory for diagnosing Paget's disease when clinical suspicion exists 1
- ALP cannot diagnose or rule out Paget's disease on its own—the diagnosis is radiological
- Many patients are discovered incidentally when elevated ALP is found on routine screening, but this still requires radiographic confirmation 1
Step 2: Role of ALP After Radiological Diagnosis
Once Paget's disease is confirmed radiographically, measure serum total ALP as the initial biochemical assessment to determine disease activity 1. The Endocrine Society gives this a strong recommendation (1|QQQQ).
Why total ALP is preferred:
- Correlates well with extent of skeletal involvement 1
- Least expensive option
- Low interassay variation
- Widely available 2
- Predicts probability of achieving normal values with bisphosphonate treatment 1
Step 3: Critical Limitation—Normal ALP Does Not Rule Out Active Disease
Approximately 15% of patients with active Paget's disease have normal serum ALP levels 3. This is a crucial pitfall that can lead to undertreatment.
In patients with monostotic disease and normal total ALP:
- Measure specific bone formation markers (bone-specific ALP or P1NP) and bone resorption markers 1
- These markers may still be normal even with active disease 1
- If biochemical markers remain normal, use serial radionuclide bone scans to assess disease activity and treatment response 1
Step 4: When to Use Alternative Markers
Measure specific bone turnover markers instead of total ALP when:
- Patient has abnormal liver or biliary tract function (total ALP will be falsely elevated from hepatic sources) 1
- Monostotic disease with normal total ALP 1
- Need to assess treatment response when total ALP is normal 3
Preferred specific markers:
- Bone formation: P1NP or bone-specific ALP (BSAP) 1
- Bone resorption: urinary markers like NTX or CTX 2, 3
Clinical Context
The disease is often asymptomatic and discovered when elevated ALP appears on routine chemistry panels 1. However, never withhold appropriate therapy solely because ALP is normal—patients can have symptomatic, active disease with normal ALP levels, as demonstrated by elevated urinary bone resorption markers and positive bone scans 3.
Post-Diagnosis Monitoring
After establishing the diagnosis and extent of disease with imaging, ALP serves as the primary monitoring tool for:
- Assessing response to bisphosphonate treatment (measure at 3-6 months) 4
- Detecting biochemical relapse (more objective than symptoms alone) 1
- Determining treatment success (aim for bone turnover below midpoint of reference range) 1
The 2019 guideline endorsed by multiple international societies confirms that total ALP is recommended as the first-line biochemical screening test when combined with liver function tests 5, reinforcing that ALP's primary role is in screening and monitoring rather than definitive diagnosis.